We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CVRx Secures Devoted Health Coverage for Barostim Therapy
Read MoreHide Full Article
Key Takeaways
CVRx gains Devoted Health coverage for Barostim across about 466,000 Medicare Advantage members.
Devoted Health coverage plus Humana now represents about 21% of Medicare Advantage enrollment for CVRx.
Barostim coverage includes the FDA-approved indication and patients enrolled in the BENEFIT-HF trial.
CVRx (CVRX - Free Report) announced that Devoted Health has issued a Medicare Advantage coverage policy for its Barostim therapy, effective July 17, 2026. The policy covers patients under the current FDA-approved indication and those enrolled in the BENEFIT-HF clinical trial, expanding reimbursement access across Devoted Health's roughly 466,000 Medicare Advantage members in 29 states.
From an investor standpoint, the announcement marks another reimbursement milestone for CVRx as broader payer coverage remains a key driver of Barostim adoption. Combined with Humana's earlier coverage policy, the company now has Medicare Advantage coverage representing about 21% of total enrollment, strengthening its commercial outlook and improving patient access while supporting long-term procedure growth.
Likely Trend of CVRX Stock Following the News
Following the announcement, shares of CVRX have traded flat. Year to date, shares of the company have plunged 57.2% compared with the industry’s 6.7% decline. However, the S&P 500 has risen 11.7% in the same timeframe.
The Devoted Health coverage policy is likely to strengthen CVRx's long-term commercial outlook by reducing reimbursement barriers for Barostim, a key factor influencing physician adoption and patient access. The addition of roughly 466,000 Medicare Advantage members across 29 states expands the therapy's reimbursable patient base, while combined coverage from Devoted Health and Humana now represents about 21% of Medicare Advantage enrollment.
CVRX currently has a market capitalization of $87.1 million.
Image Source: Zacks Investment Research
More on the News
The newly announced policy extends coverage beyond Barostim's existing FDA-approved indication to include patients participating in the landmark BENEFIT-HF clinical trial, a move that could support both commercial adoption and clinical research enrollment. Devoted Health is the eighth-largest Medicare Advantage insurer in the United States, with nearly 466,000 members across 29 states, making it a meaningful addition to CVRx's reimbursement footprint.
According to management, the latest policy builds on Humana's earlier Medicare Advantage coverage decision. The announcement also follows a series of reimbursement milestones for Barostim in 2026, including the rollout of Category I CPT codes for the procedure in January and CMS approval of Category B Investigational Device Exemption coverage for patients enrolled in the BENEFIT-HF trial.
More on the Barostim Therapy
Barostim is the first FDA-approved neuromodulation therapy designed to improve symptoms in heart failure patients by delivering electrical pulses to baroreceptors in the carotid artery, helping restore balance to the autonomic nervous system. Meanwhile, the BENEFIT-HF trial is evaluating the therapy in a significantly broader heart failure population through a randomized, controlled study expected to enroll about 2,500 patients across nearly 150 centers in the United States and Germany.
The trial aims to assess whether Barostim can reduce major clinical events such as hospitalization, transplant and mortality while improving outcomes in patients beyond the current approved indication.
Industry Prospects Favoring the Market
Going by the data provided by Grand View Research, the global neuromodulation devices market size was valued at $6.4 billion in 2025 and is projected to grow from $7 billion in 2026 to $13.9 billion by 2033, at a CAGR of 10.4% from 2026 to 2033.
The rising government funding for R&D activities in these devices, increasing prevalence of neurological disorders and technological advancements in these devices are driving the market growth.
Recently, CVRx reported encouraging second-quarter 2026 results, with total revenues rising 16% year over year to $15.7 million and U.S. revenues increasing 21% to $14.8 million. The company also expanded its U.S. active implanting centers to 258 from 240 a year ago, reflecting steady commercial adoption of Barostim. Additionally, Humana became the first Medicare Advantage insurer to issue a dedicated coverage policy for Barostim therapy, effective May 1, 2026, marking an important reimbursement milestone for the company.
CVRX’s Zacks Rank & Key Picks
Currently, CVRX has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.
View the Zacks #1 Rank List
Image: Bigstock
CVRx Secures Devoted Health Coverage for Barostim Therapy
Key Takeaways
CVRx (CVRX - Free Report) announced that Devoted Health has issued a Medicare Advantage coverage policy for its Barostim therapy, effective July 17, 2026. The policy covers patients under the current FDA-approved indication and those enrolled in the BENEFIT-HF clinical trial, expanding reimbursement access across Devoted Health's roughly 466,000 Medicare Advantage members in 29 states.
From an investor standpoint, the announcement marks another reimbursement milestone for CVRx as broader payer coverage remains a key driver of Barostim adoption. Combined with Humana's earlier coverage policy, the company now has Medicare Advantage coverage representing about 21% of total enrollment, strengthening its commercial outlook and improving patient access while supporting long-term procedure growth.
Likely Trend of CVRX Stock Following the News
Following the announcement, shares of CVRX have traded flat. Year to date, shares of the company have plunged 57.2% compared with the industry’s 6.7% decline. However, the S&P 500 has risen 11.7% in the same timeframe.
The Devoted Health coverage policy is likely to strengthen CVRx's long-term commercial outlook by reducing reimbursement barriers for Barostim, a key factor influencing physician adoption and patient access. The addition of roughly 466,000 Medicare Advantage members across 29 states expands the therapy's reimbursable patient base, while combined coverage from Devoted Health and Humana now represents about 21% of Medicare Advantage enrollment.
CVRX currently has a market capitalization of $87.1 million.
Image Source: Zacks Investment Research
More on the News
The newly announced policy extends coverage beyond Barostim's existing FDA-approved indication to include patients participating in the landmark BENEFIT-HF clinical trial, a move that could support both commercial adoption and clinical research enrollment. Devoted Health is the eighth-largest Medicare Advantage insurer in the United States, with nearly 466,000 members across 29 states, making it a meaningful addition to CVRx's reimbursement footprint.
According to management, the latest policy builds on Humana's earlier Medicare Advantage coverage decision. The announcement also follows a series of reimbursement milestones for Barostim in 2026, including the rollout of Category I CPT codes for the procedure in January and CMS approval of Category B Investigational Device Exemption coverage for patients enrolled in the BENEFIT-HF trial.
More on the Barostim Therapy
Barostim is the first FDA-approved neuromodulation therapy designed to improve symptoms in heart failure patients by delivering electrical pulses to baroreceptors in the carotid artery, helping restore balance to the autonomic nervous system. Meanwhile, the BENEFIT-HF trial is evaluating the therapy in a significantly broader heart failure population through a randomized, controlled study expected to enroll about 2,500 patients across nearly 150 centers in the United States and Germany.
The trial aims to assess whether Barostim can reduce major clinical events such as hospitalization, transplant and mortality while improving outcomes in patients beyond the current approved indication.
Industry Prospects Favoring the Market
Going by the data provided by Grand View Research, the global neuromodulation devices market size was valued at $6.4 billion in 2025 and is projected to grow from $7 billion in 2026 to $13.9 billion by 2033, at a CAGR of 10.4% from 2026 to 2033.
The rising government funding for R&D activities in these devices, increasing prevalence of neurological disorders and technological advancements in these devices are driving the market growth.
CVRx, Inc. Price
CVRx, Inc. price | CVRx, Inc. Quote
Other News
Recently, CVRx reported encouraging second-quarter 2026 results, with total revenues rising 16% year over year to $15.7 million and U.S. revenues increasing 21% to $14.8 million. The company also expanded its U.S. active implanting centers to 258 from 240 a year ago, reflecting steady commercial adoption of Barostim. Additionally, Humana became the first Medicare Advantage insurer to issue a dedicated coverage policy for Barostim therapy, effective May 1, 2026, marking an important reimbursement milestone for the company.
CVRX’s Zacks Rank & Key Picks
Currently, CVRX has a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and The Cooper Companies (COO - Free Report) .
Globus Medical, currently sporting a Zacks Rank #1 (Strong Buy), reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.
GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.
West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.
WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.
The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.
COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.